Data gathered: December 22
AI Stock Analysis - ADMA Biologics (ADMA)
Analysis generated July 22, 2024. Powered by Chat GPT.
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics. The company's primary focus is on the treatment of immune deficiencies and infectious diseases, particularly through its plasma-derived products. As a player in a niche but crucial segment of the pharmaceutical industry, ADMA Biologics aims to cater to unmet medical needs while maintaining a robust pipeline for future products.
Stock Alerts - ADMA Biologics (ADMA)
 |
ADMA Biologics | December 12 Price is down by -5.2% in the last 24h. |
|
ADMA Biologics | December 9 AI Score is up by 26.1% in the last couple of days. |
|
ADMA Biologics | December 8 AI Score is up by 28.6% in the last couple of days. |
|
ADMA Biologics | December 2 Price is down by -6.4% in the last 24h. |
Alternative Data for ADMA Biologics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 69 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 13 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 13 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 20,214 | Sign up | Sign up | Sign up |
| Twitter Followers | 505 | Sign up | Sign up | Sign up |
| Twitter Mentions | 21 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 64 | Sign up | Sign up | Sign up |
| Linkedin Employees | 394 | Sign up | Sign up | Sign up |
About ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
| Price | $17.40 |
| Target Price | Sign up |
| Volume | 6,940,000 |
| Market Cap | $4.11B |
| Year Range | $5.98 - $22.62 |
| Dividend Yield | 0% |
| PE Ratio | 64.44 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit FacilityDecember 20 - Investing.com |
 |
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and AlnylamDecember 19 - Yahoo |
ADMA Biologics : Announces Partial Paydown of Senior Term Loan Credit Facility Form 8 KDecember 19 - Finnhub |
|
 |
Wellington Management Group LLP Sells 478,935 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)December 18 - ETF Daily News |
|
ADMA Biologics, Inc. (NASDAQ:ADMA) Sees Significant Decrease in Short InterestDecember 15 - ETF Daily News |
|
HighTower Advisors LLC Buys 25,492 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)December 15 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 120M | 60M | 60M | 36M | 39M | 0.000 |
| Q2 '24 | 107M | 50M | 57M | 32M | 35M | 0.130 |
| Q1 '24 | 82M | 43M | 39M | 18M | 24M | 0.080 |
| Q4 '23 | 74M | 43M | 31M | -18M | 16M | -0.080 |
| Q3 '23 | 67M | 43M | 25M | 2.6M | 11M | 0.010 |
Insider Transactions View All
| Grossman Adam S filed to sell 1,989,007 shares at $21.1. November 22 '24 |
| Tade Brad L. filed to sell 199,433 shares at $21.2. November 22 '24 |
| Guiheen Lawrence P. filed to sell 153,941 shares at $18.5. September 11 '24 |
| Kestenberg-Messina Kaitlin M. filed to sell 449,088 shares at $16.9. August 30 '24 |
| Grossman Jerrold B filed to sell 467,305 shares at $17.3. August 30 '24 |
Similar companies
Read more about ADMA Biologics (ADMA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of ADMA Biologics?
The Market Cap of ADMA Biologics is $4.11B.
What is ADMA Biologics' PE Ratio?
As of today, ADMA Biologics' PE (Price to Earnings) ratio is 64.44.
What is the current stock price of ADMA Biologics?
Currently, the price of one share of ADMA Biologics stock is $17.40.
How can I analyze the ADMA stock price chart for investment decisions?
The ADMA stock price chart above provides a comprehensive visual representation of ADMA Biologics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ADMA Biologics shares. Our platform offers an up-to-date ADMA stock price chart, along with technical data analysis and alternative data insights.
Does ADMA offer dividends to its shareholders?
As of our latest update, ADMA Biologics (ADMA) does not offer dividends to its shareholders. Investors interested in ADMA Biologics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of ADMA Biologics?
Some of the similar stocks of ADMA Biologics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.